Survey shows over 80% of Europeans have reservations about having laser eye surgery

Article

Germany?s Professor Gerhard Auffarth.

A survey conducted by Opinion Health, 2010 on behalf of The European Society of Cataract and Refractive Surgeons has revealed that 80% of Europeans have reservations about having laser eye surgery themselves despite 69% believing it to be a safe and established procedure.

Approximately, two out of three people cited some degree of fear at the prospect of laser vision correction as the reason for their caution, while about a third said that they would need more information.

ESCRS president José Guell of Barcelona said: “LASIK can be a life changing procedure, but these survey results show that people do not understand just how safe and effective modern LASIK is in the hands of a well qualified and experienced laser eye surgeon. We hope that our new campaign, LASIK Safe in Our Hands will help to bridge the information gap so that more people might benefit from good vision without glasses or contact lenses.”

The survey also highlighted that over 70% of Europeans think that wearing glasses or contact lenses makes it difficult to participate in some sports and nearly 75% think that wearing glasses is inconvenient in different weather conditions. Buying and replacing glasses and contact lenses is perceived to be expensive by 84% of people taking part in the survey (n=1000) but only about a third think that laser eye surgery provides a cheaper alternative if the cost is spread over a ten year period.

www.LASIKSafeinOurHands.com

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.